| Literature DB >> 29018475 |
Abdul H Kandhro1,2, Watshara Shoombuatong2, Chanin Nantasenamat2, Virapong Prachayasittikul3, Pornlada Nuchnoi1,4.
Abstract
Background: Dyslipidemia is one of the major forms of lipid disorder, characterized by increased triglycerides (TGs), increased low-density lipoprotein-cholesterol (LDL-C), and decreased high-density lipoprotein-cholesterol (HDL-C) levels in blood. Recently, MicroRNAs (miRNAs) have been reported to involve in various biological processes; their potential usage being a biomarkers and in diagnosis of various diseases. Computational approaches including text mining have been used recently to analyze abstracts from the public databases to observe the relationships/associations between the biological molecules, miRNAs, and disease phenotypes. Materials andEntities:
Keywords: dyslipidemia; interaction network; lipid diseases; microRNA; text mining
Year: 2017 PMID: 29018475 PMCID: PMC5615414 DOI: 10.3389/fgene.2017.00116
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Workflow diagram of study.
Figure 2Text-mining framework.
Figure 3Workflow diagram of CyTargetLinker regulatory interaction network.
Figure 4Workflow diagram of BiNGO Gene ontology.
Summary of the number of miRNAs, diseases/identifiers, miRNA-disease associations, and number of papers.
| Total No. of miRNAs | 148 |
| No. of disease/Identifier groups | 9 |
| miRNA-disease occurrence/Associations | 227 |
| No. of papers in pairs associations | 313 |
| Total No. of papers | 414 |
Figure 5All 227 miRNA-lipid disease associations by P-values. Red circles and green circles represent miRNAs and diseases, blue square represents lipid diseases/identifiers, respectively, according to the number of corresponding text mined annotated papers. Each linked pair represents a miRNA-disease association with edge-weighted measurement by P-values to visualize the strength of the miRNA-disease association. The miRNAs either connect one disease or more than one disease; it shows that a single miRNA or group of miRNAs may be involved with one or more than one disease.
Figure 6Top 20 miRNA-lipid disease association of P-values. Red circles and green circles represent miRNAs and diseases, blue square represents lipid diseases/identifiers, respectively, according to the number of corresponding, text-mined annotated papers. Each linked pair represents an miRNA-disease association with edge-weighted measurement by P-values to visualize the strength of the miRNA-disease association. The higher strength is shown in HDL-Cholesterol and Triglyceride groups paired with miRNAs.
Top 20 significant associations between miRNA and disease P-value by one-sided Fisher's exact method.
| 1 | miRNA-33a | HDL-Cholesterol | 7 | 3.40E-05 |
| 2 | miRNA-33a/b | HDL-Cholesterol | 7 | 3.40E-05 |
| 3 | miRNA-144 | HDL-Cholesterol | 3 | 3.40E-05 |
| 4 | miRNA-223 | HDL-Cholesterol | 3 | 3.40E-05 |
| 5 | miRNA-33b | HDL-Cholesterol | 3 | 3.40E-05 |
| 6 | miRNA-185 | HDL-Cholesterol | 2 | 3.40E-05 |
| 7 | miRNA-96 | HDL-Cholesterol | 2 | 3.40E-05 |
| 8 | miRNA-103 | Triglyceride | 2 | 5.60E-05 |
| 9 | miRNA-122a | Triglyceride | 2 | 5.60E-05 |
| 10 | miRNA-17-92 | Triglyceride | 2 | 5.60E-05 |
| 11 | miRNA-375 | Triglyceride | 2 | 5.60E-05 |
| 12 | miRNA-122 | Triglyceride | 5 | 1.59E-04 |
| 13 | miRNA-33 | HDL-Cholesterol | 16 | 2.98E-03 |
| 14 | miRNA-200c | LDL | 2 | 7.69E-03 |
| 15 | miRNA-126 | Hyperlipidemia | 2 | 8.80E-03 |
| 16 | miRNA-30c | Hyperlipidemia | 2 | 8.80E-03 |
| 17 | miRNA-145 | Dyslipidemia | 2 | 1.36E-02 |
| 18 | miRNA-29b | LDL | 3 | 1.80E-02 |
| 19 | miRNA-155 | Hyperlipidemia | 2 | 2.80E-02 |
| 20 | miRNA-146a | LDL | 4 | 3.31E-02 |
CyTargetLinker's validated and predicted MTIs.
| Fisher's Set-1 | 4,356 | 5,399 | 361 | 2,851 | 2,174 |
| Fisher's Set-2 | 4,082 | 4,941 | 94 | 2,756 | 2,078 |
| Fisher's Set-3 | 6,064 | 8,361 | 1,043 | 4,353 | 2,951 |
| Fisher's Set-4 | 4,889 | 6,295 | 727 | 3,315 | 2,242 |
CyTargetLinker results of defined number of targets by threshold functionality.
| Fisher's Set-1 | 22 |
| Fisher's Set-2 | 8 |
| Fisher's Set-3 | 57 |
| Fisher's Set-4 | 25 |
| Total | 112 |
Figure 7Defined number of predicted and validated target genes from Top 20 significant miRNAs. Among the 20 significant miRNAs, only 18 showed a defined number of targets at threshold 3 functionality modes on CyTargetLinker and Cytoscape. The miRNAs and their accession numbers are in red circles; pink hexagonal shapes indicate their regulatory interaction (targeted mRNAs/genes). The different colors of arrows show regulatory interactions for the identification based on miRNA validated and predicted databases (miRTarBase, MicroCosm, and TargetScan). Each miRNA targets mRNA/genes and the high number of such targets is shown in (C) where miRNA-155 has 31 targets and miRNA-200c has 11. In (D) miRNA-103 has 11 targets. Single targets also were found as shown in (A) for miRNA-144 and (B) for miRNA-33b and miRNA-185.
Top 20 significant miRNAs and their predicted and validated targets by CyTargetLinker extension network analysis.
| hsa-miR-122 | |
| hsa-miR-145 | |
| hsa-miR-33, hsa-miR-33a | |
| hsa-miR-144 | |
| hsa-miR-96 | |
| hsa-miR-223 | |
| hsa-miR-185 | |
| hsa-miR-33b | |
| hsa-miR-155 | |
| hsa-miR-200c | |
| hsa-miR-122a | |
| hsa-miR-29b | |
| hsa-miR-146a | |
| hsa-miR-103 | |
| hsa-miR-375 | |
| hsa-miR-126 | |
| hsa-miR-30c |
Top significant related gene ontology terms of CyTargetLinker targeted genes analyzed by BINGO on Cytoscape.
| 9891 | Positive regulation of biosynthetic process | 55 | 12 | 1.83E-06 |
| 31324 | Negative regulation of cellular metabolic process | 55 | 12 | 3.88E-06 |
| 9892 | Negative regulation of metabolic process | 55 | 12 | 1.02E-05 |
| 44260 | Cellular macromolecule metabolic process | 55 | 25 | 1.33E-05 |
| 15248 | Sterol transporter activity | 20 | 2 | 6.56E-05 |
| 5159 | Insulin-like growth factor receptor binding | 24 | 2 | 1.57E-04 |
| 46627 | Negative regulation of insulin receptor signaling pathway | 24 | 2 | 2.34E-04 |
| 33344 | Cholesterol efflux | 20 | 2 | 2.49E-04 |
| 30226 | Apolipoprotein receptor activity | 8 | 1 | 4.50E-04 |
| 8286 | Insulin receptor signaling pathway | 20 | 2 | 7.39E-04 |
| 30301 | Cholesterol transport | 20 | 2 | 8.68E-04 |
| 42632 | Cholesterol homeostasis | 20 | 2 | 1.10E-03 |
| 55092 | Sterol homeostasis | 20 | 2 | 1.10E-03 |
| 34188 | Apolipoprotein A-I receptor activity | 20 | 1 | 1.12E-03 |
| 6629 | Lipid metabolic process | 20 | 5 | 1.93E-03 |
| 55088 | Lipid homeostasis | 20 | 2 | 2.18E-03 |
| 5319 | Lipid transporter activity | 20 | 2 | 2.32E-03 |
| 10887 | Negative regulation of cholesterol storage | 8 | 1 | 2.70E-03 |
| 5899 | Insulin receptor complex | 24 | 1 | 2.70E-03 |
| 32869 | Cellular response to insulin stimulus | 20 | 2 | 3.17E-03 |
| 34186 | Apolipoprotein A-I binding | 20 | 1 | 3.37E-03 |
| 10875 | Positive regulation of cholesterol efflux | 8 | 1 | 3.59E-03 |
| 32365 | Intracellular lipid transport | 8 | 1 | 3.59E-03 |
| 10874 | Regulation of cholesterol efflux | 8 | 1 | 4.04E-03 |
| 32373 | Positive regulation of sterol transport | 8 | 1 | 4.04E-03 |
| 32376 | Positive regulation of cholesterol transport | 8 | 1 | 4.04E-03 |
| 34204 | Lipid translocation | 20 | 1 | 4.49E-03 |
| 10885 | Regulation of cholesterol storage | 8 | 1 | 5.38E-03 |
| 34380 | High-density lipoprotein particle assembly | 20 | 1 | 5.61E-03 |
| 43559 | Insulin binding | 20 | 1 | 5.61E-03 |
| 10888 | Negative regulation of lipid storage | 8 | 1 | 6.28E-03 |
| 70325 | Lipoprotein receptor binding | 8 | 1 | 7.17E-03 |
| 31325 | Positive regulation of cellular metabolic process | 8 | 3 | 7.27E-03 |
| 32868 | Response to insulin stimulus | 20 | 2 | 8.31E-03 |
| 9893 | Positive regulation of metabolic process | 8 | 3 | 8.42E-03 |
| 32370 | Positive regulation of lipid transport | 8 | 1 | 8.51E-03 |
| 6869 | Lipid transport | 20 | 2 | 1.05E-02 |
| 34185 | Apolipoprotein binding | 20 | 1 | 1.23E-02 |
| 10876 | Lipid localization | 20 | 2 | 1.23E-02 |
| 16071 | mRNA metabolic process | 24 | 3 | 1.30E-02 |
| 32368 | Regulation of lipid transport | 8 | 1 | 1.74E-02 |
| 9892 | Negative regulation of metabolic process | 24 | 4 | 2.70E-02 |